Live Breaking News & Updates on Michael Landsittel
Stay updated with breaking news from Michael landsittel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Avidity Partners Management LP lessened its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 18.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 615,000 shares of the biotechnology company’s stock after selling 136,600 shares during the quarter. Blueprint Medicines accounts for approximately 2.1% of Avidity […] ....
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation, nine have issued a buy recommendation and one has […] ....
Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Equities researchers at Zacks Research issued their Q2 2024 earnings per share estimates for shares of Blueprint Medicines in a report released on Tuesday, May 14th. Zacks Research analyst A. Chakraborty forecasts that the biotechnology company will earn ($1.40) per share for the quarter. The consensus estimate […] ....
Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Analysts at Zacks Research issued their Q2 2024 earnings per share estimates for Blueprint Medicines in a report released on Tuesday, May 14th. Zacks Research analyst A. Chakraborty anticipates that the biotechnology company will post earnings of ($1.40) per share for the quarter. The consensus estimate for […] ....
Stephens assumed coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report published on Tuesday, MarketBeat.com reports. The firm issued an overweight rating and a $140.00 price objective on the biotechnology company’s stock. Other equities analysts have also issued research reports about the company. SVB Leerink raised Blueprint Medicines from an underperform […] ....